<DOC>
	<DOC>NCT00484276</DOC>
	<brief_summary>The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.</brief_summary>
	<brief_title>Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>This is a phase II, open-label, non-randomized study that will be conducted in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen , that will be conducted using Simon's two-stage design method.</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Patients &gt;18 years affected by malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatous, mixed Prior intrapleural cytotoxic agents including bleomycin not considered systemic chemotherapy ECOG Performance status 0 2 Adequate baseline bone marrow, hepatic and renal function, defined as follows: Neutrophils &gt; 1.5 x 10^9/L and platelets &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN in absence of liver metastasis AST and/or ALT &lt; 5 x ULN in presence of liver metastasis Serum creatinine &lt; 1.5 x ULN Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (take as reference "Technical data sheet human albumin" specifically used in Pharmacy Department for NGRhTNF dilution) Patients may have had prior therapy providing the following conditions are met: Chemotherapy and radiotherapy: washout period of 28 days Surgery: washout period of 14 days Normal cardiac function and absence of uncontrolled hypertension Patients must give written informed consent to participate in the study Concurrent anticancer therapy Patients may not receive any other investigational agents while on study Clinical signs of CNS involvement Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol Pregnancy or lactation. Patients both males and females with reproductive potential (i.e. menopausal for less than 1year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>malignant pleural mesothelioma</keyword>
</DOC>